Clinical trials: Hair Diseases
Alopecia Areata
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.
- Trial name
- NCT04034134
- Testing
- Jaktinib Hydrochloride Tablets
- Where
- 2 sites in China
- Volunteers
- 111 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Thin Hair, Hair Loss
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth by applying a serum daily on the scalp of men and women with thinning hair. The main aims of this trial are: 1.
- Conditions
- Thin Hair, Hair Loss, Alopecia, Thinning Hair
- Trial name
- NCT07228156
- Testing
- Xtresse Serum
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451021
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia
LLLT for Alopecia of the Eyebrow in Women
The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system…
- Trial name
- NCT04897555
- Testing
- LLLT
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Alopecia
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido.
- Trial name
- NCT02014584
- Testing
- Dutasteride
- Where
- 18 sites in Chile, Hong Kong and 3 more
- Volunteers
- 117 people
- Sponsor
- Stiefel, a GSK Company
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Phase II clinical trial
- Trial name
- ELAN (NCT02919735)
- Testing
- CG 428 cutaneous solution
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Legacy Healthcare SA
Excessive Hairiness, Vascular Lesion
Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias.
- Conditions
- Excessive Hairiness, Vascular Lesion, Pigmented Lesions, Acne Vulgaris
- Trial name
- Anthelia (NCT06655129)
- Testing
- intense pulsed light
- Where
- 5 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eurofeedback
Hypotrichosis
Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow Hypotrichosis
A Prospective, single arm, and interventional Clinical Trial
- Trial name
- NCT07775989
- Testing
- dermo cosmetic product
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Quantum Aesthetics Cosmetics
Androgenetic Alopecia
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- Trial name
- NCT04945226
- Testing
- Finasteride 1mg Tablet, IVL3001
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AAJP (NCT07617597)
- Testing
- Deuruxolitinib
- Where
- 18 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Sun Pharma Japan Limited
Hair Transplantation, Seborrheic Dermatitis
A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients
A total of 120 Chinese male subjects aged 18-50 years who have undergone hair transplantation are planned to be enrolled in this study.
- Conditions
- Hair Transplantation, Seborrheic Dermatitis, Scalp Care
- Trial name
- NCT07641686
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- ChinaNorm
Severe Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body.
- Trial name
- NCT07772492
- Testing
- Upadacitinib
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- AbbVie
Androgenic Alopecia
Computer-Assisted Hair Restoration Study Using ARTAS System
Prospective, multi-center, up to 4 investigational centers evaluating the performance of the ARTAS System in Hair Restoration Procedures.
- Trial name
- NCT05938569
- Testing
- Hair restoration
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Venus Concept
Androgenetic Alopecia (AGA)
Phase II Study Evaluating the Efficacy and Safety of KX-826
This is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 in Chinese adult male patients with AGA.
- Trial name
- NCT05940506
- Testing
- KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia
Study of EPI-001 in Patients With Androgenetic Alopecia
This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.
- Trial name
- NCT07618195
- Testing
- EPI-001
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Epibiotech
Prostate Cancer, Hirsutism
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Bicalutamide 50 mg tablet and Casodex following a 50 mg dose in healthy subjects under fasting conditions.
- Trial name
- NCT00959335
- Testing
- Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA), Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz